[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551646":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":84,"collaborators":86,"id":89,"slug":11,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":11,"enrollmentInfo":97,"targetDuration":11,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"CytomX Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CX-801","EXPERIMENTAL",null,[13],"Drug: CX-801",{"label":15,"type":10,"description":11,"interventionNames":16},"CX-801 + pembrolizumab",[13,17],"Drug: pembrolizumab",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Investigational drug",[9,15],{"type":20,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"pembrolizumab","Standard of Care Therapy",[15],[28],"KEYTRUDA®",[30],{"name":31,"affiliation":5,"role":32},"Monika Vainorius, MD","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Karen Deane","CONTACT","650-515-3185","clinicaltrials@cytomx.com",[40,54,64,74],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":11},"The Melanoma and Skin Cancer Institute","RECRUITING","Englewood","Colorado","80113","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-104.98776,39.64777,{"lat":52,"lon":51},{"facility":55,"status":42,"city":56,"state":57,"zip":58,"country":46,"countryCode":47,"cosmosGeoPoint":59,"geoPoint":63,"contacts":11},"University of Pittsburgh Hillman Cancer Center","Pittsburgh","Pennsylvania","15232",{"type":49,"coordinates":60},[61,62],-79.99589,40.44062,{"lat":62,"lon":61},{"facility":65,"status":42,"city":66,"state":67,"zip":68,"country":46,"countryCode":47,"cosmosGeoPoint":69,"geoPoint":73,"contacts":11},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":49,"coordinates":70},[71,72],-86.78444,36.16589,{"lat":72,"lon":71},{"facility":75,"status":42,"city":76,"state":77,"zip":78,"country":46,"countryCode":47,"cosmosGeoPoint":79,"geoPoint":83,"contacts":11},"START Dallas Fort Worth, LLC","Fort Worth","Texas","76104",{"type":49,"coordinates":80},[81,82],-97.32085,32.72541,{"lat":82,"lon":81},{"type":85,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[87],{"name":88,"class":6},"Merck Sharp & Dohme LLC","100551646",false,"NCT06462794","First In Human Study of CX-801 in Advanced Solid Tumors","An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors","Inclusion Criteria:\n\n* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Adequate organ function\n* Additional inclusion criteria may apply\n\nExclusion Criteria:\n\n* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Prior PD-1\u002F PD-(L)1 inhibitor treatment discontinued due to grade 3 or higher immune related adverse event\n* Systemic anticancer treatment within 4 weeks or 5 half lives prior to first dose of study treatment\n* Investigational drug or device within 4 weeks prior to first dose of study treatment\n* Radiation within 2 weeks prior to first dose of study treatment\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply","ALL","18 Years",{"count":98,"type":99},121,"ESTIMATED","INTERVENTIONAL",[102],"PHASE1","The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.",[105],"Solid Tumor, Adult","2026-06-25",{"date":108,"type":109},"2026-06-29","ACTUAL",{"date":111,"type":109},"2024-08-28",{"date":113,"type":99},"2029-06-30",{"name":5,"class":6},4]